This report is based on public company disclosures, filings and announcements reviewed by GSN; figures are as stated by the company and have not been independently verified.

Rocket Pharmaceuticals Inc (NASDAQ: RCKT) announced on September 15, 2026, that it has achieved alignment with the U.S. Food and Drug Administration regarding the pivotal Phase 2 trial of its gene therapy candidate RP-A501 for the treatment of Danon disease. The company stated that this regulatory milestone clarifies the framework for the study and establishes a clear path toward potential accelerated approval.

Rocket Pharmaceuticals is a fully integrated commercial-stage biotechnology company based in Cranbury, New Jersey. The company develops genetic medicines for rare and life-threatening diseases, with a strategic focus on inherited cardiovascular disorders. Danon disease is a rare genetic disorder that affects the heart, skeletal muscle, and brain. The company noted that its cardiovascular portfolio includes three clinical-stage gene therapy programs targeting various forms of cardiomyopathy.

According to the press release, the FDA confirmed that the pivotal efficacy population for the trial will consist of 12 male patients treated with RP-A501 at a recalibrated dose of 3.8 × 10¹³ genome copies per kilogram using commercial-grade product. The agency also confirmed that the first three patients already treated under the modified protocol count toward this 12-patient pivotal population. This leaves nine additional patients to be enrolled and treated. Rocket Pharmaceuticals expects to complete the dosing of the remaining patients by mid-2027.

The primary assessment for the trial will occur at 12 months. The study will utilize previously established co-primary endpoints, which include myocardial LAMP2 protein expression and a 10% reduction from baseline in left ventricular mass index. The company stated that these endpoints are intended to support a potential accelerated approval pathway.

The modified protocol incorporates a recalibrated dose and an optimized immunomodulatory regimen. This regimen includes rituximab, sirolimus, and corticosteroids, along with enhanced eligibility criteria and safety monitoring. The recalibrated dose was selected based on analytical characterization of the Phase 2 commercial-grade product, including its full-particle content. The company cited nonclinical bridging data to support the pharmacologic activity of this dose. In a Danon disease mouse model, administration of the Phase 2 material at the specified dose resulted in cardiac LAMP2B protein expression comparable to that observed at a higher dose.

Safety data reviewed by the FDA included results from the first three patients treated under the modified protocol. All three patients completed at least four weeks of follow-up and were discharged following protocol-specified observation. The company reported that no clinical or laboratory evidence of thrombotic microangiopathy or capillary leak syndrome had been observed. Following this review, the FDA confirmed continued enrollment and dosing under the modified protocol.

Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharmaceuticals, stated that the FDA’s confirmation of the pivotal efficacy framework marks an important milestone for RP-A501 and the Danon disease community. He added that the initial clinical experience at the recalibrated dose and supportive product-bridging data further reinforce the path forward.

Rocket Pharmaceuticals plans to provide a comprehensive update on the Danon disease program during a virtual investor webinar on October 6, 2026, at 4:30 p.m. ET. The company said additional information, including webcast access details, will be available in the Investors section of its website.

For investors, this alignment reduces regulatory uncertainty regarding the trial design and sample size. It confirms that the company can proceed with a smaller, focused patient population while maintaining the endpoints necessary for regulatory consideration. The timeline for completing dosing by mid-2027 provides a specific horizon for the next major data readout.

Sources